BOV Stock Chart & Stats
€3.30
-€0.04(-1.20%)
At close: 4:00 PM EDT
€3.30
-€0.04(-1.20%)
Day’s Range― - ―
52-Week Range€1.46 - €4.14
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€148.95M
Enterprise Value€169.99
Total Cash (Recent Filing)€31.14M
Total Debt (Recent Filing)€39.46M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding41,912,040
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.71Price Target Upside73.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€52.17M
Bulls Say, Bears Say
Bulls Say
AYON 510(k) Expansion (power Liposuction)The FDA 510(k) expansion for AYON to support power-assisted liposuction materially broadens the product's addressable market and positions AYON as an all-in-one platform. That structural capability can accelerate device placements, raise consumable volumes, and deepen surgeon reliance over the next 2–6 months and beyond.
Razor-and-blades Consumable ModelApyx’s razor-and-blades model creates recurring, higher-frequency revenue from single-use handpieces and disposables tied to installed systems. Durable consumable demand supports predictable revenue per installed unit, leverages gross-margin potential, and aligns incentives for continued clinical adoption and training investment.
Deleveraged Balance Sheet And Cash RunwaySharp debt reduction and a reported $31.1M cash balance materially lower solvency risk and increase strategic flexibility. With leverage down, management can fund AYON commercialization, clinical studies, and international registrations without immediate refinancing, extending the window to reach sustainable cash generation.
Bears Say
Negative Operating And Free Cash FlowPersistently negative operating and free cash flow means the business still consumes cash despite revenue gains. Over the medium term, sustained cash burn could force funding rounds or constrain commercial investment, making profitability and cash-conversion improvements critical to avoid dilution or curtailed growth.
Ongoing GAAP Losses And Weak MarginsThe company remains GAAP loss-making with deeply negative margins and negative ROE. Until operating margins sustainably convert positive, Apyx lacks durable earnings power to self-fund expansion, leaving results sensitive to mix shifts, tariff headwinds, and any slowdown in AYON adoption.
Tariff & International Registration/execution RiskPersistent tariffs and lengthy, country-specific registration timelines slow international uptake and can compress margins. Execution delays abroad reduce near-term consumable volume growth from overseas placements and raise the risk that expected international contributions underperform the plan, pressuring medium-term revenue visibility.
Apyx Medical News
BOV FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was €1.46 and its highest was €4.14 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is €148.95M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on May 07, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.095 by €0.052.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.07.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 41,912,040 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.095. Following the earnings report the stock price went down -2.419%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in DE:BOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.76%
Trailing 12-Months
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
BOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive operational and financial momentum driven by the AYON commercial launch and strong Surgical Aesthetics demand: double-digit revenue growth, expanding gross margins, reduced operating losses, improved adjusted EBITDA, a raised full-year revenue guide, and a healthy cash balance with a runway into 2027. Offsetting risks include a remaining GAAP net loss, tariff-related cost pressure, an expected long-term decline in the OEM business, some domestic generator sales decline/reclassification, and adoption timing dependency on the forthcoming power-liposuction label and international registrations. Overall, the positives—particularly the robust AYON ramp, international traction, margin expansion, and upgraded guidance—significantly outweigh the negatives.View all DE:BOV earnings summariesBOV Stock 12 Month Forecast
Average Price Target
€5.71
▲(73.14% Upside)